Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMC
Chan et al. show that natural killer (NK) cells can be reprogrammed by breast cancer cells to promote metastasis. Reprogramming can be blocked by targeting NK cell inhibitory receptors TIGIT or KLRG1 or inhibiting DNA methyltransferases, which ...
J Cell Biol . 2020 Jul 9;219(9):e202001134. doi: 10.1083/jcb.202001134 Cancer cells educate natural killer cells to a metastasis-promoting cell state Isaac S Chan Isaac S Chan 1 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 2 Department of Cell Biology and Center for Cell Dynamics, Johns Hopkins University School of Medicine, Baltimore, MD Find articles by Isaac S Chan 1, 2, ✉ , Hildur Knútsdóttir Hildur Knútsdóttir 4 Department of Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Balt
saved by
related reading
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PubMedpubmed.ncbi.nlm.nih.gov
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
- Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancernature.com
- Frontiers | The Role of NK Cells and Innate Lymphoid Cells in Brain Cancerfrontiersin.org
- CNIH4: a novel biomarker connected with poor prognosis and cell proliferation in patients with lower-grade gliomapmc.ncbi.nlm.nih.gov
- Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review - PMCpmc.ncbi.nlm.nih.gov
- Immunotherapy for Cancer - NCIcancer.gov
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanomanature.com
- Lopez-Colon.pdffredhutch.org
- Epigenetic regulation during cancer transitions across 11 tumour typesnature.com
- Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance - PMCncbi.nlm.nih.gov